Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands

Por Gendzekhadze, Ketevan, Norman, Paul J., Abi-Rached, Laurent, Graef, Thorsten, Moesta, Achim K., Layrisse, Zulay, Parham, Peter
Publicado em 2009

Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 Epitope of MHC class I

Por Moesta, Achim K., Graef, Thorsten, Abi-Rached, Laurent, Older Aguilar, Anastazia M., Guethlein, Lisbeth A., Parham, Peter
Publicado em 2010

Mutation at Positively Selected Positions in the Binding site for HLA-C Shows KIR2DL1 is a More Refined but Less Adaptable NK cell Receptor than KIR2DL3()

Por Hilton, Hugo G., Vago, Luca, Older Aguilar, Ana, Moesta, Achim K., Graef, Thorsten, Abi Rached, Laurent, Norman, Paul J., Guethlein, Lisbeth A., Fleischhauer, Katharina, Parham, Peter
Publicado em 2012

A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors

Por Deutsch, Eric, Moyal, Elizabeth Cohen-Jonathan, Gregorc, Vanesa, Zucali, Paolo Andrea, Menard, Jean, Soria, Jean-Charles, Kloos, Ioana, Hsu, Jeff, Luan, Ying, Liu, Emily, Vezan, Remus, Graef, Thorsten, Rivera, Sofia
Publicado no Oncotarget (2016)

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

Por Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Flinn, Ian W., Burger, Jan A., Tran, Anh, Clow, Fong, James, Danelle F., Graef, Thorsten, Friedberg, Jonathan W., Rai, Kanti, O’Brien, Susan
Publicado no Blood (2015)

KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A(*)11 while diminishing avidity for HLA-C

Por Graef, Thorsten, Moesta, Achim K., Norman, Paul J., Abi-Rached, Laurent, Vago, Luca, Older Aguilar, Anastazia M., Gleimer, Michael, Hammond, John A., Guethlein, Lisbeth A., Bushnell, David A., Robinson, Philip J., Parham, Peter
Publicado em 2009

Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study

Por Ribrag, Vincent, Kim, Won Seog, Bouabdallah, Reda, Lim, Soon Thye, Coiffier, Bertrand, Illes, Arpad, Lemieux, Bernard, Dyer, Martin J. S., Offner, Fritz, Felloussi, Zakia, Kloos, Ioana, Luan, Ying, Vezan, Remus, Graef, Thorsten, Morschhauser, Franck
Publicado no Haematologica (2017)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

Por Richardson, Paul G., Bensinger, William I., Huff, Carol Ann, Costello, Caitlin L., Lendvai, Nikoletta, Berdeja, Jesus G., Anderson, Larry D., Siegel, David S., Lebovic, Daniel, Jagannath, Sundar, Laubach, Jacob P., Stockerl‐Goldstein, Keith E., Kwei, Long, Clow, Fong, Elias, Laurence, Salman, Zeena, Graef, Thorsten, Bilotti, Elizabeth, Vij, Ravi
Publicado no Br J Haematol (2018)

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Por O’Brien, Susan, Furman, Richard R, Coutre, Steven E, Sharman, Jeff P, Burger, Jan A, Blum, Kristie A, Grant, Barbara, Richards, Donald A, Coleman, Morton, Wierda, William G, Jones, Jeffrey A, Zhao, Weiqiang, Heerema, Nyla A, Johnson, Amy J, Izumi, Raquel, Hamdy, Ahmed, Chang, Betty Y, Graef, Thorsten, Clow, Fong, Buggy, Joseph J, James, Danelle F, Byrd, John C
Publicado em 2013

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

Por Brown, Jennifer R., Moslehi, Javid, Ewer, Michael S., O'Brien, Susan M., Ghia, Paolo, Cymbalista, Florence, Shanafelt, Tait D., Fraser, Graeme, Rule, Simon, Coutre, Steven E., Dilhuydy, Marie‐Sarah, Cramer, Paula, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C., Treon, Steven, Liu, Emily Y., Chang, Stephen, Bista, Amulya, Vempati, Rama, Boornazian, Lisa, Valentino, Rudolph, Reddy, Vijay, Mahler, Michelle, Yang, Huiying, Graef, Thorsten, Burger, Jan A.
Publicado no Br J Haematol (2018)

Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes

Por Norman, Paul J., Abi-Rached, Laurent, Gendzekhadze, Ketevan, Hammond, John A., Moesta, Achim K., Sharma, Deepti, Graef, Thorsten, McQueen, Karina L., Guethlein, Lisbeth A., Carrington, Christine V.F., Chandanayingyong, Dasdayanee, Chang, Yih-Hsin, Crespí, Catalina, Saruhan-Direskeneli, Güher, Hameed, Kamran, Kamkamidze, Giorgi, Koram, Kwadwo A., Layrisse, Zulay, Matamoros, Nuria, Milà, Joan, Park, Myoung Hee, Pitchappan, Ramasamy M., Ramdath, D. Dan, Shiau, Ming-Yuh, Stephens, Henry A.F., Struik, Siske, Tyan, Dolly, Verity, David H., Vaughan, Robert W., Davis, Ronald W., Fraser, Patricia A., Riley, Eleanor M., Ronaghi, Mostafa, Parham, Peter
Publicado em 2009